Based on 60 years cancer diagnostic expertise, 30 years of molecular pathology and 10 years next generation sequencing, OncoDNA’s services fot clinical trials are: Clinical Testing, Precision Enrolment and Knowledge Driven Medicine.
Reducing delays and cost in patient recruitment
Accessing a pool of patients fully characterized to serve you R&D and clinical trials
Building your CDx strategy using our technical regulator expertise
Offering NGS and molecular pahtology as stand-alone or integrated assay
Two exclusive solutions to improve the characterisation clinical trial’s patients and to ease treatment monitoring.
Meet your recruitment targets & deadlines by granting treatment access to fully characterised patients.
OncoKDM: Make it your data interpretation pipeline, from patient to trials meta-analyses.
We support Biopharma companies driving access to market and provide better outcomes for patients
by providing comprehensive genomic profiling to support clinical and treatment decision (CDS)
gathering physician practices and patient outcomes efficiently (RWE)
facilitating real-time monitoring of genomic and clinical response to treatment (resistance, progression, relapse and residual cancer burden)
measuring real impact of a treatment on improved outcomes and quality of care (Clinical Outcome Assessment - COA)
improving disease, therapies and market awareness
At OncoDNA, we always want to stay on top, which is why we are constantly trying to keep up to date with the latest scientific news. And these news we like to share them with you ... We provide you with personalised information, you read what you need.read more news
Interested in more scientific information?Subscribe to our newsletter
Combination of solid and liquid biopsy genomic profiling for tumor heterogeneity characterization
The clinical impact of using complex molecular profiling strategies in routine oncology practice ... [READ MORE]
"Aiding physicians to identify HRAS and other mutations in HNSCC is an essential element of Kura’s clinical development strategy. Streamlining screening processes facilitates timely access to important medical information that could help oncologists and their patients in making treatment decisions"
The study met its predefined success criteria and has been amended to continue enrolling HRAS mutant HNSCC pts, as well as pts with SCC, other than HNSCC, with HRAS mutations into a new Cohort 3. (ESMO 22 october 2018)